FR2829505B1 - Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih) - Google Patents

Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)

Info

Publication number
FR2829505B1
FR2829505B1 FR0210592A FR0210592A FR2829505B1 FR 2829505 B1 FR2829505 B1 FR 2829505B1 FR 0210592 A FR0210592 A FR 0210592A FR 0210592 A FR0210592 A FR 0210592A FR 2829505 B1 FR2829505 B1 FR 2829505B1
Authority
FR
France
Prior art keywords
hiv
analyzing
new method
human immunodeficiency
phenotypic characteristics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0210592A
Other languages
English (en)
Other versions
FR2829505A1 (fr
Inventor
Francois Clavel
Fabrizio Mammano
Esther Race
Elisabeth Dam
Veronique Obry
Virginie Trouplin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103970A external-priority patent/FR2816635A1/fr
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to FR0210592A priority Critical patent/FR2829505B1/fr
Publication of FR2829505A1 publication Critical patent/FR2829505A1/fr
Application granted granted Critical
Publication of FR2829505B1 publication Critical patent/FR2829505B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0210592A 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih) Expired - Fee Related FR2829505B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0210592A FR2829505B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103970A FR2816635A1 (fr) 2000-11-10 2001-03-23 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
FR0210592A FR2829505B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)

Publications (2)

Publication Number Publication Date
FR2829505A1 FR2829505A1 (fr) 2003-03-14
FR2829505B1 true FR2829505B1 (fr) 2006-05-19

Family

ID=27589510

Family Applications (3)

Application Number Title Priority Date Filing Date
FR0210592A Expired - Fee Related FR2829505B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR0210591A Expired - Fee Related FR2829504B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteistiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR0210593A Expired - Fee Related FR2829506B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(hiv)

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR0210591A Expired - Fee Related FR2829504B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteistiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR0210593A Expired - Fee Related FR2829506B1 (fr) 2001-03-23 2002-08-26 Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(hiv)

Country Status (1)

Country Link
FR (3) FR2829505B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136516A1 (en) * 2008-12-01 2010-06-03 454 Life Sciences Corporation System and method for detection of HIV integrase variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6103462A (en) * 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
GB9909793D0 (en) * 1999-04-28 1999-06-23 Glaxo Group Ltd Improved assay and reagents therefor

Also Published As

Publication number Publication date
FR2829506A1 (fr) 2003-03-14
FR2829506B1 (fr) 2006-05-19
FR2829504A1 (fr) 2003-03-14
FR2829504B1 (fr) 2006-05-19
FR2829505A1 (fr) 2003-03-14

Similar Documents

Publication Publication Date Title
DE60208794D1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DK0980203T3 (da) Antimikrobiel forebyggelse og behandling af humant immundeficiensvirus og andre infektiöse sygdomme
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
EA200000840A1 (ru) Антивирусные производные пиримидина
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ID26043A (id) Turunan-turunan 1,3,5-triazina tertrisubstitusi untuk pengobatan infeksi-infeksi hiv
CA2253490A1 (fr) Utilisation d'il-12 ifn-.alpha. pour le traitement de maladies infectieuses
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
AU2305202A (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
AU2002223052A1 (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV)
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
DE50015096D1 (de) Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
FR2829504B1 (fr) Nouvelle methode d'analyse des caracteistiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829501B1 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
FR2829502B1 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
WO2002022076A3 (fr) Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida
FR2829503B1 (fr) Nouvelee methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
ITTO20020284A0 (it) Procedimento per la sterilizzazione e la neutralizzazione di odori dell'aria.
EP1407042A4 (fr) Dispositif et methodes de surveillance d'une therapie antiretrovirale inhibitrice de la protease et determination de decisions therapeutiques dans le traitement du vih/sida
RU2000125255A (ru) 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека
FR2821553B1 (fr) Utilisation d'un ou plusieurs shogaol (s) en tant qu'aphrodisiaque

Legal Events

Date Code Title Description
TQ Partial transmission of property
CL Concession to grant licences
ST Notification of lapse

Effective date: 20121130